دورية أكاديمية
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
| العنوان: | Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer |
|---|---|
| المؤلفون: | Lheureux, Stephanie, Matei, Daniela E., Konstantinopoulos, Panagiotis A., Wang, Ben X., Gadalla, Ramy, Block, Matthew S., Jewell, Andrea, Gaillard, Stephanie L., McHale, Michael, McCourt, Carolyn, Temkin, Sarah, Girda, Eugenia, Backes, Floor J., Werner, Theresa L., Duska, Linda, Kehoe, Siobhan, Colombo, Ilaria, Wang, Lisa, Li, Xuan, Wildman, Rachel, Soleimani, Shirin, Lien, Scott, Wright, John, Pugh, Trevor, Ohashi, Pamela S., Brooks, David G., Fleming, Gini F. |
| المساهمون: | Obstetrics and Gynecology, School of Medicine |
| المصدر: | Publisher |
| بيانات النشر: | BMJ |
| سنة النشر: | 2022 |
| المجموعة: | Indiana University - Purdue University Indianapolis: IUPUI Scholar Works |
| مصطلحات موضوعية: | immunotherapy, biomarkers, tumor, clinical trials, phase II as topic, drug therapy, combination, genital neoplasms, female |
| الوصف: | Background Combining immunotherapy and antiangiogenic agents is a promising treatment strategy in endometrial cancer. To date, no biomarkers for response have been identified and data on post-immunotherapy progression are lacking. We explored the combination of a checkpoint inhibitor (nivolumab) and an antiangiogenic agent (cabozantinib) in immunotherapy-naïve endometrial cancer and in patients whose disease progressed on previous immunotherapy with baseline biopsy for immune profiling. Patients and methods In this phase II trial (ClinicalTrials.gov NCT03367741, registered December 11, 2017), women with recurrent endometrial cancer were randomized 2:1 to nivolumab with cabozantinib (Arm A) or nivolumab alone (Arm B). The primary endpoint was Response Evaluation Criteria in Solid Tumors-defined progression-free survival (PFS). Patients with carcinosarcoma or prior immune checkpoint inhibitor received combination treatment (Arm C). Baseline biopsy and serial peripheral blood mononuclear cell (PBMC) samples were analyzed and associations between patient outcome and immune data from cytometry by time of flight (CyTOF) and PBMCs were explored. Results Median PFS was 5.3 (90% CI 3.5 to 9.2) months in Arm A (n=36) and 1.9 (90% CI 1.6 to 3.4) months in Arm B (n=18) (HR=0.59, 90% CI 0.35 to 0.98; log-rank p=0.09, meeting the prespecified statistical significance criteria). The most common treatment-related adverse events in Arm A were diarrhea (50%) and elevated liver enzymes (aspartate aminotransferase 47%, alanine aminotransferase 42%). In-depth baseline CyTOF analysis across treatment arms (n=40) identified 35 immune-cell subsets. Among immunotherapy-pretreated patients in Arm C, non-progressors had significantly higher proportions of activated tissue-resident (CD103+CD69+) ɣδ T cells than progressors (adjusted p=0.009). Conclusions Adding cabozantinib to nivolumab significantly improved outcomes in heavily pretreated endometrial cancer. A subgroup of immunotherapy-pretreated patients identified by baseline immune ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | Journal for ImmunoTherapy of Cancer; Lheureux, S., Matei, D. E., Konstantinopoulos, P. A., Wang, B. X., Gadalla, R., Block, M. S., Jewell, A., Gaillard, S. L., McHale, M., McCourt, C., Temkin, S., Girda, E., Backes, F. J., Werner, T. L., Duska, L., Kehoe, S., Colombo, I., Wang, L., Li, X., … Fleming, G. F. (2022). Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. Journal for ImmunoTherapy of Cancer, 10(3), e004233. https://doi.org/10.1136/jitc-2021-004233Test; https://hdl.handle.net/1805/41677Test |
| الإتاحة: | https://doi.org/10.1136/jitc-2021-004233Test https://hdl.handle.net/1805/41677Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.122050FA |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |